Chapter 2

Shifting paradigms for suppressing fibrosis in kidney transplants:
Supplementing perfusion solutions with antifibrotic drugs

L.L. van Leeuwen
H.G.D. Leuvenink
P. Olinga
M.J.R. Ruigrok

Front. in Med. 2022. (8); 2917
**Introduction**

Kidney transplantation is a life-saving procedure that significantly improves the lives of patients who suffer from end-stage renal disease, which is characterized by glomerulosclerosis and tubulointerstitial fibrosis and represents the last stage of chronic kidney disease. The increase in life span conferred by kidney transplantation has been estimated to be approximately 10 years, and ranges from 3 to 17 years depending on patient group. Kidneys are the most frequently transplanted organ in the world, with over 100,000 transplantations in 2019. Organs for kidney transplantation are predominantly obtained through donation after brain death (DBD), although other sources exist as well, including the use of kidneys from living donors. Still, there remains a tremendous demand for donor kidneys, far exceeding their supply.

In recent years, immense efforts have been focused towards addressing the demand for donor kidneys. One of the most promising approaches is to use kidneys from donation after circulatory death (DCD) donors. These kidneys, however, suffer from more severe ischemia and reperfusion injury as well as interstitial fibrosis and tubular atrophy, after which we describe currently available approaches for preserving donor kidneys. We then present an evaluation of selected compounds. To identify promising compounds, we analyzed publications describing the effects of antifibrotic molecules in precision-cut kidneys slices, which are viable explants that can be cultured ex vivo for up to a few days whilst retaining functional and structural features. LY2109761, galunisertib, imatinib, nintedanib, and butaprost were shown to exert antifibrotic effects in slices within a relatively short timeframe (<48 hours) and are therefore considered to be excellent candidates for follow-up ex vivo machine perfusion studies.

**Abstract**

Great efforts have been made toward addressing the demand for donor kidneys. One of the most promising approaches is to use kidneys from donation after circulatory death donors. These kidneys, however, suffer from more severe ischemia and reperfusion injury than those obtained via donation after brain death and are thus more prone to develop interstitial fibrosis and tubular atrophy. Even though machine perfusion is increasingly used to reduce ischemia and reperfusion injury, there are no effective treatments available to ameliorate interstitial fibrosis and tubular atrophy, forcing patients to resume dialysis, undergo re-transplantation, or suffer from premature death. Safe and effective antifibrotic therapies are therefore greatly desired. We propose a new therapeutic approach in which machine perfusion solutions are supplemented with antifibrotic compounds. This allows the use of higher concentrations than those used in humans whilst eliminating side effects in other organs. To the authors’ knowledge, no one has reviewed whether such an approach could reduce interstitial fibrosis and tubular atrophy; we therefore set out to explore its merit. In this review, we first provide background information on ischemia and reperfusion injury as well as interstitial fibrosis and tubular atrophy, after which we describe currently available approaches for preserving donor kidneys. We then present an evaluation of selected compounds. To identify promising compounds, we analyzed publications describing the effects of antifibrotic molecules in precision-cut kidneys slices, which are viable explants that can be cultured ex vivo for up to a few days whilst retaining functional and structural features. LY2109761, galunisertib, imatinib, nintedanib, and butaprost were shown to exert antifibrotic effects in slices within a relatively short timeframe (<48 hours) and are therefore considered to be excellent candidates for follow-up ex vivo machine perfusion studies.
Ischemia and reperfusion injury

To understand the complex pathophysiological processes underlying chronic allograft nephropathy, it is essential to recognize the main source of tissue damage: IRI. During DCD donation, IRI starts immediately after withdrawing life support (Figure 2). This causes the donor to enter a withdrawal (agonal) period of hemodynamic instability until cardiac function ceases. At some point during this process, the blood pressure becomes insufficient to support organ function, starting the so-called ‘functional’ warm ischemia time. Circulatory arrest follows, marking the start of the ‘standard’ warm ischemia time, which extends until the onset of cold in situ perfusion of abdominal organs19,20. After surgical removal, donor kidneys are stored and transported in ice-cold preservation solution. Cold preservation reduces, but does not eliminate, cellular injury 21. In fact, prolonged warm and cold ischemia is associated with DGF, graft failure, and mortality after kidney transplantation22–25. Upon transplantation, the graft is anastomosed to the arteries of the recipient, establishing reperfusion. Reperfusion, however, does not directly restore physiological conditions. As a matter of fact, it initially exacerbates damage caused by ischemia.

Despite the lack of antifibrotic therapies, there are approaches available to reduce damage in donor kidneys, the most effective one being the use of machine perfusion—an increasingly popular method to preserve grafts, especially those obtained from suboptimal donors such as DCD donors18. This technique could be further improved by adding antifibrotic drugs to perfusion solutions, reducing the risk of systemic side effects. To the authors’ knowledge, no one has reviewed whether such an approach could reduce IF/TA in kidney transplants; we therefore set out to explore its merit. In this review, we first provide background information on the sources of damage in kidney transplants and the development of IF/TA, after which we describe currently available approaches for preserving donor kidneys. We then present an evaluation of antifibrotic compounds that appear promising for use during machine perfusion, followed by an outline of recommendations for future research to accelerate developments. We must be swift to realize this paradigm shift.

Ischemia

Ischemia occurs when the blood supply to tissue becomes restricted, causing a shortage of oxygen that is needed to produce adenosine triphosphate (ATP). As a result of ischemia, cells switch from highly efficient aerobic respiration (i.e., 29 to 30 ATP molecules per glucose molecule) to far less efficient anaerobic respiration (i.e., 2 ATP molecules per glucose molecule)26,27. This causes a decline in intracellular ATP levels and increased levels of lactate, which contribute to intracellular acidosis and cell membrane injury (Figure 3)28. ATP depletion also affects intracellular calcium (Ca²⁺) levels because Ca²⁺ pumps, which are ATP-dependent, cannot pump Ca²⁺ out of cells29. Increased levels of intracellular Ca²⁺ subsequently cause activation of various calcium-dependent enzymes, such as calpains, endonucleases, and phospholipases.
Interstitial fibrosis and tubular atrophy

It is clear that IRI promotes cell death by apoptosis and/or necrosis, especially in tubular and glomerular cells. Apart from that, IRI triggers an immune response, activating both the innate and adaptive immune system. IRI also affects the structural integrity of kidney tissue, as marked by swelling of endothelial cells, loss of their glycocalyx, and degradation of the cytoskeleton. In response to these forms of damage, molecular processes supporting wound-healing, also known as ‘fibrogenesis’, are activated in an attempt to restore tissue integrity and function.

Normal wound-healing: fibrogenesis and epithelial dedifferentiation

Fibrogenesis represents a well-coordinated, multicellular regenerative response that is triggered upon injury (Figure 4). When renal tissue gets injured, an inflammatory response is elicited, involving various immune cells, such as T-cells, dendritic cells, macrophages, and neutrophils. Triggered by inflammatory cytokines, including but not limited to tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), interleukin 6 (IL-6), and transforming growth factor beta 1 (TGF-β1), these immune cells are recruited to affected sites and become activated to remove tissue debris as well as dead and damaged cells. TGF-β1 in particular also promotes the accumulation of myofibroblasts, which are key effector cells in wound-healing. Myofibroblasts have been shown to arise from various sources, namely: proliferation and differentiation of resident interstitial fibroblasts (50%), infiltration and differentiation of fibrocytes (35%), endothelial-to-mesenchymal transition (EndoMT) (20%), and epithelial-to-mesenchymal transition (E-MT) (15%).

Reperfusion

Upon reperfusion, the blood supply is restored, and the ischemic environment induces an inflammatory response. The re-introduction of oxygen, rewarming of the kidney graft, and pH normalization is detrimental to the previously ischemic cells. Sudden increases in oxygen levels lead to extensive ROS production. The production of ROS is normally counteracted by antioxidants, but the high levels after reperfusion overwhelm this protection mechanism. pH normalization leads to a further increase in intracellular Ca^2+ levels that, together with the generated ROS, further activate calcium-dependent enzymes (e.g., calpains etc.). Activated calpains promote inflammation and damage cells by selectively degrading a large number of intracellular proteins, including signaling proteins, cytoskeletal proteins, and transcription factors. The electron transport chain may also become unstable. This causes the formation of mitochondrial permeability transition pores which, in turn, promote the release of cytochrome C into the cytosol to activate caspases—the key effector proteins in apoptosis.

Figure 3. Ischemia and reperfusion injury as a result of donation after circulatory death. ATP: adenosine triphosphate; ROS: reactive oxygen species. Created with BioRender.com.

Figure 4. Kidney repair after ischemia and reperfusion injury by means of fibrogenesis and tubular dedifferentiation. TNF-α: tumor necrosis factor; IL-6: interleukin; IL-1β: interleukin 1β; TGF-β: transforming growth factor. Created with BioRender.com.
enchymal transition (EMT) (5%) 42-45. The extent of EndoMT and EMT, however, remains controversial and it is currently unclear whether these processes play a substantial role in humans. Once myofibroblasts become activated, characterized by de novo expression of alpha smooth muscle actin (α-SMA), these cells aim to restore tissue integrity by producing and secreting ECM proteins, especially collagens and fibronectins 43.

The provisional, collagen-rich matrix provides a scaffold for cell growth (e.g., to facilitate tubular regeneration). In normal conditions, the renewal rate of tubular epithelial cells is low. This rate, however, drastically increases after (ischemic) injury, with the aim of restoring the tubular epithelium via dedifferentiation 46. Indeed, fully differentiated tubular epithelial cells have been shown to repair proximal tubules without the contribution of intratubular stem cells. This process comprises four stages. Stage one is characterized by apoptosis or necrosis of damaged tubular epithelial cells as well as inflammation. In the second stage, tubular cells flatten and lose their brush border and polarity. EMT has also been shown to occur in this stage. Stage three is marked by increased secretion of growth factors, which stimulate tubular epithelial cells to enter the cell-division cycle. In the last stage, the tubules become repopulated with daughter cells, and morphological features of tubular structures recover 46. After these processes, kidney function is restored.

Wound-healing gone rogue: interstitial fibrosis and tubular atrophy

In some cases, the wound-healing process becomes severely dysregulated, resulting in the uncontrolled deposition of ECM proteins into the intertubular, extravagular space of the kidney (Figure 5) 57, 48. This phenomenon is called ‘interstitial fibrosis’. Fibrosis is a disorder in which the excessive deposition of ECM proteins afflicts kidney architecture and function. The root-cause of the shift from fibrogenesis to fibrosis remains unclear. Some aspects, however, have been shown to play a role, such as the persistence and duration of injury. Chronic injury, for example, contributes to the unbridled recruitment of immune cells as well as activation of myofibroblasts. Given enough time, the ECM changes with respect to its composition (i.e., collagen and fibronectin-rich), organization (i.e., densely crosslinked fibers), and stiffness. In fibrosis, these changes to the ECM are thought to have passed a point-of-no-return, wherein the ECM itself starts to perpetuate myofibroblast activation. One of the key mediators during this pathophysiological process is TGF-β, which binds to its cell membrane type I and II receptor, causing receptor phosphorylation and so activation of its downstream signalling mediators SMAD2 and SMAD3 (Figure 5) 49.

Interstitial fibrosis is often observed together with tubular atrophy, as both pathologies can be the result of IRI 50. TA is characterized by the disappearance and/or flattening of tubular epithelial cells, contraction of tubular lumens, and thickening as well as wrinkling of tubular basement membranes (Figure 5) 55. Unsurprisingly, these processes reduce the tubular reabsorption of water and small molecules. Like fibrosis, the pathogenesis of TA involves various mechanisms, of which the extent of involvement has not been fully elucidated. Apoptosis, for example, could become persistent, effectively reducing the number of cells as a result of (chronic) injury 50. Schelling et al. have also observed increased levels of senescence in remaining epithelial cells 50. Senescent cells have lost the ability to divide and therefore further impede tubular dedifferentiation. Sometimes, chronic histological damage is already visible as early as three months post-transplantation 51.

Current strategies for preserving donor kidneys

Throughout the years, various preservation techniques have been developed to facilitate the storage and transport of donor organs (Figure 6). Static cold storage (SCS) is the most commonly applied preservation technique and has been the accepted clinical standard for organ preservation in most countries since the 1960s 52. However, the past decade has revealed the benefits of using machine perfusion. In fact, machine perfusion for preserving deceased donor kidneys is the current standard of clinical care in The Netherlands, as it shows better outcomes than SCS 53.
to reduced serum creatinine levels post-transplantation and a reduced risk of graft failure. On top of that, the use of HMP significantly increased the 1-year graft survival rate compared to SCS (94% vs. 90%, p=0.04).

Nowadays, HMP is frequently performed using oxygenated perfusion solution, as it has been shown to promote ATP synthesis, preserve mitochondrial homeostasis and reduce interstitial fibrosis in porcine kidneys. Jochmans et al. demonstrated that oxygenation (100% oxygen at 100 mL/min) lessened post-transplant complications and significantly increased the 1-year graft survival rate compared to HMP without oxygen (95% vs. 89%, p=0.028). Therefore, oxygenated HMP may be a promising therapy to reduce the odds of developing IF/TA, but this will require long-term follow-up studies.

Last but not least, HMP allows for sampling of the perfusate to assess the viability, as elegantly shown by Moers et al. who analyzed glutathione-S-transferase, N-acetyl-β-D-glucosaminidase, and heart-type fatty acid binding protein to predict DGF. Emerging techniques, such as proteomics, also appear promising, as reported by van Leeuwen et al., who found out that the HMP perfusate composition associates with the 1-year transplant outcome.

**Normothermic machine perfusion**

Normothermic machine perfusion (NMP) represents an advanced form of preservation. During NMP, organs are perfused with a blood-based solution at 37°C, mimicking the physiological conditions to support metabolic activity and organ function. The perfusate composition between NMP protocols varies greatly, as the exact metabolic needs of an isolated kidney are still not fully characterized. Studies have revealed the importance of using an oxygen carrier (e.g., red blood cells or artificial oxygen carriers), even when supraphysiological concentrations of oxygen are used. Short-term outcomes for porcine kidneys that were subjected to NMP have shown to be superior compared to those subjected to SCS. Studies comparing HMP and NMP have not revealed differences in transplant outcomes yet.

Like HMP, NMP also allows for sampling and subsequent analysis of perfusate. NMP, however, offers another benefit as it can be used to assess kidney function (i.e., urine production, creatinine clearance, and fractional sodium excretion) as metabolism is restored. Carefully monitoring graft function during NMP and measuring biomarkers in the perfusate can facilitate decision-making during transplantation. In spite of that, standardized viability criteria are lacking because no one has managed to predict post-transplant outcomes yet. Although NMP itself seems to offer superior graft preservation in comparison to SCS, supplementing perfusate with pharmacologically-active compounds may further improve the preservation of metabolically active donor kidneys.
Suppressing the onset of fibrosis ex vivo

Current approaches for suppressing fibrosis are mostly focused on minimizing damage to kidney grafts (e.g., donor age, ischemia time, and machine perfusion). With the shortage of donor kidneys, however, these strategies are not sufficient. Supplementing NMP solutions with antifibrotic drugs could be a promising strategy to suppress the onset of fibrosis and, in turn, reduce graft failure. Unfortunately, research into this area is limited, as conventional models such as cell cultures and animal studies have a limited predictive value when it comes to assessing the efficacy of antifibrotic drugs. Cell cultures are useful for investigating cell-specific responses but do not recapitulate the intricate cell-cell and cell-matrix interactions as well as mechanical cues that are observed in fibrosis. Of course, animal models using rodents provide considerably more useful data, owing to the presence of a functional immune system and interorgan crosstalk, yet interspecies differences remain.

We therefore carefully considered the models used whilst selecting relevant literature on antifibrotic compounds. It was also important to consider the potency of compounds as well as the rate at which antifibrotic effects were produced. These factors are crucial, as the maximum NMP time is currently limited to 24 hours.

To identify promising antifibrotic compounds, we reviewed literature describing the use of precision-cut kidney slices (PCKS). PCKS are viable explants, with consistent dimensions that can be used to study fibrogenesis and fibrosis as well as the efficacy of antifibrotic compounds. The advantage of PCKS is that they contain a large number and diversity of cells, accurately reflecting the renal architecture. On top of that, PCKS can be prepared from (fibrotic) human tissue, creating an unprecedented opportunity to validate the molecular basis of antifibrotic drug candidates in humans. PCKS can also be quickly prepared in a reproducible manner by means of a specialized workflow (Figure 7).

In short, cylindrical cores are prepared from kidney tissue using a biopsy puncher, after which they are placed into a Krumdieck tissue slicer and sliced under hypothermic and oxygenated conditions. PCKS are subsequently transferred to culture plates containing fresh and pre-warmed culture medium and are then incubated at 37 °C, 80% O₂, and 5% CO₂, whilst being gently shaken. Considering the advantages and flexibility of PCKS (e.g., using different timepoints, compound concentrations etc.), it becomes clear that their use represents a valuable intermediate step before assessing antifibrotic compounds in an NMP setup.

Small molecule drugs

Several drug candidates have been shown to have antifibrotic effects on PCKS (Table 1). Each of these small-molecule drugs produced effects already within 48 hours of incubation. We hypothesize that these compounds could be promising for use during NMP, as each inhibited fibrosis via the TGF-β/SMAD signaling pathway (Figure 8). The respective studies will be discussed in this section.

| Compound name | Concentrations | Species | Incubation time | Effect on fibrosis | Target | Reference |
|---------------|----------------|---------|-----------------|-------------------|--------|-----------|
| LY2109761     | 5µM            | Mouse   | 48h             | ↓                 | TGF-β receptor I/II | 83       |
| Galunisertib  | 10µM           | Human   | 48h             | ↓                 | TGF-β receptor I/II | 84,85    |
| Imatinib      | 10 µM          | Human   | 48h             | ↓                 | PDGF receptor     | 85       |
| Nintedanib    | 1 µM           | Human   | 48h             | ↓                 | PDGF receptor     | 81       |
| Butaprost     | 50 µM          | Human   | 48h             | ↓                 | EP₂ receptor      | 86       |

LY2109761 is an oral small-molecule TGF-β receptor type I/II dual inhibitor that has been extensively studied in cancer research. Some studies, however, have shown that this molecule also reduces the extent of pulmonary and renal fibrosis. Stribos et al., for example, demonstrated that LY2109761 exerted strong antifibrotic effects in PCKS prepared from mouse tissue, as it significantly downregulated the
expression of various fibrosis-related genes (e.g., Col1a1, Serpinh1, Fn-1, Acta-2, Serpine1) within 48 hours of incubation, without affecting the mitochondrial activity. The authors also observed a significant reduction in the expression of HSPA7—a molecular chaperone that is required for collagen synthesis. Unfortunately, it is not known whether this compound also produced effects after 24 hours of incubation because this timepoint was not included in the study. It also remains unclear whether LY2109761 has antifibrotic effects in PCKS prepared from human tissue. Follow-up studies should address these points as well as the lacking information with respect to side effects (e.g., the extent of cell death, effects on cell proliferation etc.).

**Galunisertib**

Galunisertib, also known as LY2157299, is an oral small-molecule inhibitor that also targets the TGF-β receptor type I/II, thereby suppressing activation of the downstream SMAD2/3 pathway. Galunisertib was initially developed as an antineoplastic drug but has also been reported to reduce fibrosis in various mouse models and PCKS. For example, Bigaeva et al. recently demonstrated that galunisertib downregulated mRNA expression of Col1a1, Acta-2, Serpinh1, Fn-1, Tgfb1, and Tgfbr in PCKS prepared from mouse tissue. The authors also observed a significant reduction in the expression of HSPA7 and phosphorylation of SMAD2. In a follow-up study conducted by the former authors, galunisertib was also shown to reduce COL1A1 mRNA expression in PCKS prepared from (fibrotic) human tissue, thereby confirming therapeutically relevant effects on fibrogenesis as well as established fibrosis.

Additionally, in neither study were harmful effects observed for galunisertib, as the mitochondrial activity and morphological features of the tissue remained intact. Having said that, the authors only analyzed samples after an incubation of 48 hours.

**Imatinib**

Imatinib is an inhibitor of the ABL1, KIT, and PDGFR tyrosine kinases. This small-molecule has been shown to target TGF-β and PDGF signaling in a SMAD-dependent and independent manner. It is frequently prescribed as an oral antineoplastic agent for treating chronic myeloid leukemia and gastrointestinal stromal tumors. Like LY2109761, imatinib has been shown to attenuate pulmonary and renal fibrosis in various models. Bigaeva et al. showed that imatinib attenuated the early onset of fibrogenesis but not established fibrosis in PCKS prepared from human tissue (within 48 hours). Imatinib also did not cause noticeable toxic effects, as assessed by histological evaluations and based on a lack of effects on mitochondrial activity. These findings are in line with Wang et al., who found out that imatinib reduced the number of resident interstitial fibroblasts and myofibroblasts, and reduced the expression and interstitial accumulation of collagen type III and IV as well as fibronectin deposition in rats. The exact mechanism-of-action, however, remains unclear, and it also remains unknown whether the effects are sufficient to attenuate fibrosis during NMP.

**Nintedanib**

Nintedanib is a small-molecule oral tyrosine kinase inhibitor that targets the VEGF, FGF, and PDGF receptors. It is used for the treatment of idiopathic pulmonary fibrosis as well as non-small-cell lung cancer, and has been shown to inhibit EMT by suppressing TGF-β/SMAD signaling. Using PCKS prepared from non-fibrotic human tissue, Bigaeva et al. showed that nintedanib significantly reduced mRNA expression of COL1A1, SERPINH1, FN-1, IL-1B, IL-6, and IL-8 after 48 hours of incubation. On top of that, COL1A1, HSPA7, and α-SMA were significantly reduced on protein level, indicating strong antifibrotic effects. These results are in agreement with Liu et al., who reported that nintedanib prevented phosphorylation of the PDGF, FGF, and VEGF receptors and reduced pro-inflammatory cytokine expression as well as macrophage infiltration. Although nintedanib seems promising due to its anti-inflammatory and antifibrotic effects in early fibrogenesis, it did not have therapeutic effects in PCKS prepared from fibrotic human tissue. However, this finding does not disqualify nintedanib as a promising candidate because it could still be useful during NMP.
Butaprost
Butaprost is a selective EP₂ receptor agonist, which can be used to modulate the COX2/PGE2 system. This system has been implicated in numerous physiological processes that occur in the kidney, such as controlling hemodynamics and regulating salt levels. PGE2 produces these effects through activation of the prostanoid receptors EP₁ and EP₃, and the expression of these receptors seems to be increased during renal injury and fibrogenesis, suggesting a protective role in fibrosis. To further explore the role of EP₂ in renal fibrosis, Jensen et al. tested butaprost in various models, including PCKS prepared from fibrogenic human tissue. The authors reported that butaprost mitigated EMT induced by TGF-β (i.e., by inhibiting SMAD2 phosphorylation, as demonstrated in vitro). They also showed that butaprost significantly reduced mRNA expression of COL1A1, FN and ACTA2, as well as protein expression of α-SMA. These findings were confirmed in vivo, and it seems to be the case that butaprost has a direct effect on TGF-β/SMAD signaling, independent of the cAMP/PKA pathway. There was also no evident toxicity observed for butaprost.

Biopharmaceuticals and beyond
Apart from small-molecule drugs, no other candidates have been tested ex vivo with the purpose of attenuating fibrogenesis and/or fibrosis in kidney tissue. Therefore, it would be particularly useful to investigate other therapeutic modalities as well, including therapeutic proteins and monoclonal antibodies, or perhaps even more advanced approaches, such as cell-based therapies or (lipid-based) nanoparticles encapsulating nucleic acids for transiently silencing or enhancing the expression of specific genes. Combinatorial therapies, affecting various stages of renal injury and fibrogenesis, could also be developed. Some of the previously described modalities have already been tested in kidneys to attenuate IRI, but not with the focus on fibrosis. Of course, there are some points to consider when developing such therapies. It is important to investigate the distribution kinetics of respective modalities in donor kidneys when administered during NMP. Cells, for instance, are unlikely to uniformly distribute through the tissue. The same applies to nanoparticles. Lastly, when supplementing perfusion solutions with therapeutic proteins and/or monoclonal antibodies, it is imperative to check whether shear stress affects their stability (e.g., denaturation, aggregation etc.).

Conclusion
IF/TA is one of the main causes of chronic graft failure after kidney transplantation, and without proper treatment, recipients are forced to resume dialysis, undergo re-transplantation, or suffer from premature death. One of the key processes in the onset of fibrosis is TGF-β1/SMAD signaling, providing an effective target for suppressing the onset of fibrosis. TGF-β receptor inhibitor galunisertib displayed clear therapeutic effects in early and late-stage fibrosis (within 48 hours). Galunisertib could therefore be a suitable candidate for suppressing the onset of fibrosis in a renal transplant setting. In the future, galunisertib should be tested in an ex vivo NMP setup using, for example, porcine kidneys. After that, the same approach can be applied to discarded human kidneys to establish whether this approach has therapeutic merit. Ultimately, the combination of oxygenated HMP and NMP supplemented with pharmacologically-active substances could lead to better long-term outcomes for patients, and therefore improve their quality of life.
55. Hoogspod, S. A., Brown, R. J. & Nicholson, M. L. Advances in kidney preservation techniques and their application in clinical practice. Transplantation Publish Ah (2021).

56. Vogel, T., Brockmann, J. G., Coussios, C. C. & Friend, P. J. Normothermic Machine Perfusion of the Liver. In Methods in Bioengineering: Organ Preservation and Reengineering (eds. Uygur, K. & Lee, C. Y.) 1–20 (Artech House, Inc. 2011).

57. Hoogspod, S. A., Brown, R. J. & Nicholson, M. L. Advances in kidney preservation techniques and their application in clinical practice. Transplantation Publish Ah (2021).

58. Venema, L. H. et al. Machine perfusion or cold storage in organ transplantation: indication, mechanisms, and future perspectives. Transpl. Int. 23, 163–170 (2010).

59. Venema, L. H. et al. Machine perfusion or cold storage in organ transplantation: indication, mechanisms, and future perspectives. Transpl. Int. 23, 163–170 (2010).

60. Tsai, M. et al. Impact of static cold storage VS hypothermic machine preservation on ischemic kidney graft: inflammatory cytokines and adhesion molecules as markers of ischemia/reperfusion tissue damage. Our preliminary results. Int. J. Surg. 11, S110–S114 (2013).

61. Giraud, S. et al. Influence of Hypoxia Preservation Temperature on Endothelial Cells and Kidney Integrity. Biomed. Res. Int. 2015, (2019).

62. Moers, C. et al. Machine Perfusion or Cold Storage in Deceased-Donor Kidney Transplantation. N. Engl. J. Med. 360, 7–19 (2009).

63. Venema, L. H. et al. Effects of Oxygen During Long-term Hypothermic Machine Perfusion in a Porcine Model of Kidney Donation After Circulatory Death. Transplantation 103, 2057–2064 (2016).

64. Thuillier, R. et al. Benefits of active oxygenation during hypothermic machine perfusion of kidneys in a reference model of deceased after cardiac death donors. J. Surg. Res. 184, 1174–1181 (2013).

65. Venema, L. H. et al. Impact of Red Blood Cells on Function and Metabolism of Porcine Deceased Donor Kidneys During Normothermic Machine Perfusion. Transplantation 2021.

66. Venema, L. H. et al. Impact of Red Blood Cells on Function and Metabolism of Porcine Deceased Donor Kidneys During Normothermic Machine Perfusion. Transplantation 2021.

67. Hameleik, T. L. et al. Renal Normothermic Machine Perfusion. Transplantation Publish Ah (2021).

68. Bhattacharjee, R. et al. Renal Protection Against Ischemia Reperfusion Injury: Hemoglobin-based Oxygen Carrier-201 Versus Blood as an Oxygen Carrier in Ex Vivo Subnormothermic Machine Perfusion. Transplantation 104, 482–489 (2020).

69. Venema, L. H. et al. Impact of Red Blood Cells on Function and Metabolism of Porcine Deceased Donor Kidneys During Normothermic Machine Perfusion. Transplantation 2021.

70. Kats, J. M. et al. Continuous Normothermic Ex Vivo Kidney Perfusion Improves Graft Function in Donation After Circulatory Death Pig Kidney Transplantation. Transplantation 101, 754–763 (2017).

71. Kats, J. M. et al. Continuous Normothermic Ex Vivo Kidney Perfusion Improves Graft Function in Donation After Circulatory Death Pig Kidney Transplantation. Transplantation 101, 754–763 (2017).

72. Urbanelles, P. et al. Normothermic Ex Vivo Kidney Perfusion Improves Early DCD Graft Function Compared with Hypothermic Machine Perfusion and Static Cold Storage. Transplantation 947–955 (2020). doi: 10.1097/TP.0000000000003066

73. Blum, M. F. et al. Comparison of normothermic and hypothermic perfusion in porcine kidneys donated after cardiac death. J. Surg. Res. 216, 35–45 (2017).
102. Richeldi, L. et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. http://dx.doi.org/10.1056/NEJMoa1402584 370, 2071–2082 (2014).
103. Shiratori, T. et al. Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review. Thorac. Cancer 11, 1720 (2020).
104. Ihara, H. et al. Nintedanib inhibits epithelial-mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF-β/Smad pathway. Respir. Investig. 58, 275–284 (2020).
105. Pool, M. et al. Infusing mesenchymal stromal cells into porcine kidneys during normothermic machine perfusion: Intact MSCs can be traced and localised to Glomeruli. Int. J. Mol. Sci. 20, (2019).
106. Tietjen, G. T. et al. Nanoparticle targeting to the endothelium during normothermic machine perfusion of human kidneys. Sci. Transl. Med. 9, 6764 (2017).
107. Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W. & Katayama, D. S. Stability of protein pharmaceuticals: an update. Pharm. Res. 27, 544–575 (2010).